14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
SGP vs BMY
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGP vs BMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BMY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)
BMY Overall Winner
6-Pillar Tally: SGP 0 – 6 BMY
Matrix Metrics: SGP 0 – 10 BMY
As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGP carries a Unified Composite Score of 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin), whereas BMY carries 53.5/100 (HOLD) at $62.93 (9.4x Forward P/E, 32.4% operating margin).
SGP
US Equity
SGP
Institutional Equity
Market Cap
N/A
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.38β · 70% Vol
Unified Composite Score
39.3 / 100
SELL
Tech 15.0
Fund 45.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.9% over 20 days), RSI 53
RSI-14: 52.7 · SMA20: $32.43 · SMA50: $28.85
BMY
NYSE
Head-to-Head Winner
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
Market Cap
$129.7B
TTM Revenue
$50.0B
Forward P/E
9.4x
Beta / 30D Vol
0.17β · 31% Vol
Unified Composite Score
53.5 / 100
HOLD
Tech 50.0
Fund 58.0
Flow 70.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.5 · SMA20: $62.28 · SMA50: $61.82
6-Pillar Scorecard Institutional Category Breakdown (SGP 0 – 6 BMY)
Columns: Metric · SGP · BMY
1. Valuation Multiples
BMY
Forward P/E
N/M
9.4x
Trailing P/E
N/M
14.1x
PEG Ratio
N/M
17.39x
EV / Revenue
N/M
3.3x
2. Growth & Scale
BMY
Revenue Growth (YoY)
N/A
+6.9%
Earnings Growth (YoY)
N/A
-2.8%
TTM Revenue (USD)
N/A
$50.0B
Market Cap
N/A
$129.7B
3. Profitability & Quality
BMY
Gross Margin
N/A
70.5%
Operating Margin
N/A
32.4%
Net Profit Margin
N/A
18.5%
Return on Equity (ROE)
N/A
44.0%
4. Balance Sheet & Cash Flow
BMY
Cash Generation (TTM)
N/A
$9.29B
Cash Flow Margin
N/A
18.6%
Net Cash / Leverage
N/A ROE
$35.2B Net Debt (1.91x D/E)
Dividend Yield
None (0.00%)
4.04%
5. Options & Positioning
BMY
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
45.6% (31st %ile)
Put/Call OI Skew
N/A
1.21x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
BMY
OpEx & R&D Intensity
N/A
38.1% of Rev ($19.1B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Institutional Equity Operator
Drug Manufacturers - General Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGP (0) vs BMY (10)
Institutional Metric
SGP
BMY
Criterion
Row Edge
Market Capitalization
Scale
N/A
$129.7B
Larger Scale
BMY
Trailing P/E Ratio
Valuation
N/M
14.1x
Lower Multiple
BMY
Forward P/E Ratio
Valuation
N/M
9.4x
Lower Multiple
BMY
Revenue Growth (YoY)
Growth
N/A
+6.9%
Higher Growth
BMY
Operating Margin (TTM)
Profitability
N/A
32.4%
Higher Margin
BMY
Net Profit Margin
Profitability
N/A
18.5%
Higher Margin
BMY
Return on Equity (ROE)
Capital Efficiency
N/A
44.0%
Higher ROE
BMY
52-Week Range Position
Momentum
66% ($17–$40)
76% ($45–$69)
Stronger Trend
BMY
Beta / 30D Volatility
Risk Regime
1.38β · 70% Vol
0.17β · 31% Vol
Lower Realized Risk
BMY
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL)
53.5 / 100 (HOLD)
Higher Composite
BMY
Trailing 12M Revenue (USD)
Operating Scale
N/A
$50.0B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
70.5%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
17.39x PEG · 3.3x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE)
$9.29B ($35.2B Net Debt (1.91x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
SGP +29.01 pp
SGP:
+34.33%
·
BMY:
+5.32%
3M Horizon
SGP +29.49 pp
SGP:
+24.77%
·
BMY:
-4.72%
6M Horizon
SGP +35.15 pp
SGP:
+44.96%
·
BMY:
+9.81%
1Y Horizon
SGP +20.6 pp
SGP:
+22.12%
·
BMY:
+1.52%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs BMY. Trailing 12-month operating profitability (SGP N/A vs BMY 32.4%) and valuation multiples (SGP N/M vs BMY 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.
SGP ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin N/A
ROE / Fwd P/E N/A · N/M
BMY ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $50.0B
Gross Margin 70.5%
Op. Margin 32.4%
ROE / Fwd P/E 44.0% · 9.4x
SGP
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
BMY
CONSOLIDATION
51d in phase · OBV NEUTRAL
Current IV
45.6%
IV Percentile
31st %ile
Put/Call OI Skew
1.21x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
5-DAY BULLISH SWING
Liq A
Dec 18 $62.5 / $67.5 Bull Call Spread
Buy 1x $62.5C · Sell 1x $67.5C · 31d
Net Entry
$197 Debit
T+5d @ +5% Move
+$100 (+51%)
Max Risk / Buffer
$197 Capped
5d Edge & Liquidity
0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME
Liq A
Dec 18 $60 / $57.5 Bull Put Spread
Sell 1x $60P · Buy 1x $57.5P · 31d
Net Entry
$61 Credit
Max Credit / Yield
+$61 (+32.3% RoM)
Max Risk / Buffer
-5.6% Cushion ($189 Mgn)
5d Edge & Liquidity
71% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD
Liq A
Dec 18 $65 / $60 Bear Put Spread
Buy 1x $65P · Sell 1x $60P · 31d
Net Entry
$211 Debit
T+5d @ -5% Drop
+$111 (+53%)
Max Risk / Buffer
$211 Capped
5d Edge & Liquidity
1.0x R:R · Liq A
Simulate 5-Day Payoff →
SGP Moat Profile
Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BMY Moat Profile
High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $129.7B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment
38.1% of Rev ($19.1B)
90D Engineering Disclosures
0 Published
Investor FAQ SGP vs BMY Key Questions & Quantitative Answers
Is SGP or BMY a better stock to buy right now?
As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGP carries a Unified Composite Score of 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin), whereas BMY carries 53.5/100 (HOLD) at $62.93 (9.4x Forward P/E, 32.4% operating margin). Technically, SGP sits in a Markup phase (RSI 52.7, UNCLASSIFIED options structure) and BMY sits in a Neutral phase (RSI 53.5, CONSOLIDATION options structure).
Does SGP or BMY have stronger revenue and earnings growth?
BMY leads the Growth & Scale pillar: SGP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BMY at +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin). On trailing 12-month operating scale, SGP generates N/A in USD-normalized revenue versus $50.0B for BMY. In operating R&D and SG&A reinvestment, SGP deploys N/A (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($19.1B) (0 disclosures) for BMY.
Is SGP or BMY cheaper on valuation?
BMY screens cheaper on headline valuation multiples. SGP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BMY trades at 9.4x Forward P/E, 14.1x Trailing P/E, 17.39x PEG, and 3.3x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGP (N/A ROE) versus BMY (44.0% ROE) capital efficiency.
How is options market volatility positioned on SGP vs BMY?
In options market volatility and institutional positioning, SGP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 70% Vol realized risk). By comparison, BMY carries 45.6% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.17β · 31% Vol realized risk).
Bristol-Myers Squibb Co. (BMY) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.